Impact of prostate volume on the active surveillance in prostate cancer

被引:0
|
作者
Beaujouan, Florent [1 ]
Bertherat, Walter [2 ]
Hammoudi, Zakaria [1 ]
Chicaud, Marie [1 ]
Descazeaud, Aurelien [1 ]
机构
[1] Univ Hosp Ctr Dupuytren, Dept Urol Surg & Androl, 16 rue Petiniaud-Beaupeyrat, F-87000 Limoges, France
[2] Perigueux Hosp Ctr, Dept Urol Surg & Androl, Perigueux, France
关键词
Prostatic neoplasms; active surveillance; prostate-specific antigen; prostatic hyperplasia; prognostic factors; FOLLOW-UP; ANTIGEN KINETICS; GUIDELINES; MANAGEMENT; DIAGNOSIS; OUTCOMES; PREDICT; UPDATE; BIOPSY; COHORT;
D O I
10.1177/20514158241303972
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: To determine the influence of the prostate volume (PVo) in the management of patients in active surveillance (AS) for prostate cancer. Materials and methods: A retrospective analysis of clinical, biological, histological and radiological data collected between 2010 and 2021 was performed for patients included in an AS protocol in a university hospital. The impact of initial PVo on the subsequent risk of exiting AS was evaluated. Results: In total, 109 patients were included in this analysis with a mean follow-up period of 52.74 +/- 31 months, 50% were out of AS by the end of the follow-up period. The risk of exiting the AS protocol was significantly associated to the PVo: patients with smaller PVo had an increased risk of exiting AS (p = 0.025). The maximal percentage of core invasion was the only initial predictive parameter for exiting the AS protocol on multivariate analysis of the global cohort (p = 0.010) and in the sub-group of patients having PVo <= 45 mL (p = 0.013). In the group having a PVo > 45 mL, no single initial parameter was significantly associated to a risk of exiting AS. Conclusion: Patients having small-sized prostate seemed to be at higher risk of exiting AS during follow-up.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Active Surveillance for Prostate Cancer: Is It Safe?
    Robinson, S.
    Laniado, M.
    Karim, O.
    Motiwala, H.
    UROLOGY, 2012, 80 (03) : S291 - S291
  • [22] Understanding Active Surveillance for Prostate Cancer
    Lai, Lillian Y.
    Shahinian, Vahakn B.
    Oerline, Mary K.
    Kaufman, Samuel R.
    Skolarus, Ted A.
    Caram, Megan E., V
    Hollenbeck, Brent K.
    JCO ONCOLOGY PRACTICE, 2021, 17 (11) : 678 - +
  • [23] Active surveillance for prostate cancer Preface
    Dall'Era, Marc A.
    Davies, Benjamin J.
    Eggener, Scott
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2018, 7 (02) : 195 - 196
  • [24] Prostate cancer: a review of active surveillance
    Lund, Lars
    Svolgaard, Niels
    Poulsen, Mads Hvid
    RESEARCH AND REPORTS IN UROLOGY, 2014, 6 : 107 - 112
  • [25] Active surveillance for prostate cancer: an update
    Merriel, Sam
    TRENDS IN UROLOGY & MENS HEALTH, 2020, 11 (01) : 8 - 11
  • [26] An integrative active surveillance of prostate cancer
    Dunn, Marisa
    Mirda, Danielle
    Whalen, Michael J.
    Kogan, Mikhail
    EXPLORE-THE JOURNAL OF SCIENCE AND HEALING, 2022, 18 (04) : 483 - 487
  • [27] Active surveillance for prostate cancer: A review
    Klotz L.
    Current Urology Reports, 2010, 11 (3) : 165 - 171
  • [28] Active surveillance for prostate cancer: For whom?
    Klotz, L
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (32) : 8165 - 8169
  • [29] Active surveillance for localized prostate cancer
    Staerman, F.
    Peyromaure, M.
    Irani, J.
    Gaschignard, N.
    Mottet, N.
    Soulie, M.
    Salomon, L.
    PROGRES EN UROLOGIE, 2011, 21 (07): : 448 - 454
  • [30] The Evolution of Active Surveillance for Prostate Cancer
    Moore, Caroline M.
    Parker, Chris
    EUROPEAN UROLOGY, 2015, 68 (05) : 822 - 823